Company research
DR REDDYS LABORATORIES LTD
CIK 1135951Updated Nov 6, 2026
SecurityRDY · NYSE · adr
RDY price & chart
Loading TradingView…
NYSE:RDY on TradingView ↗About the company
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ↗
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | 671,000,000Source | 668,000,000Source | 548,000,000Source | 311,000,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | —Source | —Source | —Source | —Source |
| Additional Financial Items | ||||
| AdjustmentsForIncomeTaxExpenseUSD | 229,000,000Source | 194,000,000Source | 186,000,000Source | 115,000,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 5,000,000Source | 5,000,000Source | 5,000,000Source | 8,000,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | 2,000,000Source | -6,000,000Source | -11,000,000Source | -10,000,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesUSD | 78,000,000Source | 80,000,000Source | 61,000,000Source | 55,000,000Source |
| GoodwillUSD | 138,000,000Source | 51,000,000Source | 52,000,000Source | 58,000,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 41,000,000Source | 27,000,000Source | 23,000,000Source | 18,000,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesINR | — | — | — | 0Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesINR | 80,646,000,000Source | 19,366,000,000Source | 49,234,000,000Source | 51,518,000,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | 3,273,000,000Source | 1,557,000,000Source | 1,372,000,000Source | 1,025,000,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | 6,000,000Source | 13,000,000Source | 1,000,000Source | 5,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 81,000,000Source | 132,000,000Source | 92,000,000Source | 58,000,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesINR | 56,156,000,000Source | 13,873,000,000Source | 68,616,000,000Source | 47,998,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | 1,099,000,000Source | 926,000,000Source | 828,000,000Source | 818,000,000Source |
| Total RevenueUSD | 3,811,000,000Source | 3,350,000,000Source | 2,992,000,000Source | 2,826,000,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | — | 0.35Source | 0.35Source |
| AverageEffectiveTaxRatenumber | 0.25Source | 0.23Source | 0.25Source | 0.27Source |
| BasicEarningsLossPerShareUSD per share | 0.79Source | 4.02Source | 3.3Source | 1.87Source |
| CurrentTaxExpenseIncomeINR | 22,581,000,000Source | 19,458,000,000Source | 12,858,000,000Source | 6,411,000,000Source |
| DeferredTaxExpenseIncomeINR | -3,042,000,000Source | -3,272,000,000Source | 2,442,000,000Source | 2,319,000,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossINR | 3,052,000,000Source | 3,381,000,000Source | -2,018,000,000Source | -2,165,000,000Source |
| DepreciationRightofuseAssetsINR | 1,249,000,000Source | 1,143,000,000Source | 879,000,000Source | 858,000,000Source |
| DilutedEarningsLossPerShareUSD per share | 0.79Source | 4.01Source | 3.3Source | 1.87Source |
| EmployeeBenefitsExpenseINR | 55,800,000,000Source | 50,300,000,000Source | 46,465,000,000Source | 38,858,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesINR | 796,000,000Source | 821,000,000Source | 644,000,000Source | 740,000,000Source |
| FinanceCostsUSD | 33,000,000Source | 21,000,000Source | 17,000,000Source | 13,000,000Source |
| FinanceIncomeUSD | 88,000,000Source | 68,000,000Source | 52,000,000Source | 41,000,000Source |
| GrossProfitUSD | 2,230,000,000Source | 1,963,000,000Source | 1,695,000,000Source | 1,500,000,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | 20,000,000Source | 1,000,000Source | 9,000,000Source | 100,000,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 229,000,000Source | 194,000,000Source | 186,000,000Source | 115,000,000Source |
| InterestExpenseINR | 2,829,000,000Source | 1,711,000,000Source | 1,428,000,000Source | 958,000,000Source |
| InterestExpenseOnLeaseLiabilitiesINR | 391,000,000Source | 256,000,000Source | 214,000,000Source | 221,000,000Source |
| OtherOperatingIncomeExpenseUSD | 51,000,000Source | 50,000,000Source | 72,000,000Source | 36,000,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | 8,000,000Source | — | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | 663,000,000Source | — | — | — |
| ProfitLossBeforeTaxUSD | 900,000,000Source | 862,000,000Source | 734,000,000Source | 426,000,000Source |
| ProfitLossFromOperatingActivitiesUSD | 842,000,000Source | 813,000,000Source | 695,000,000Source | 389,000,000Source |
| ResearchAndDevelopmentExpenseUSD | 320,000,000Source | 274,000,000Source | 236,000,000Source | 230,000,000Source |
Filing attachments
rdy0959_ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com November 5, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Ref: Disclosure u…
Read attachment ↗rdy0958_ex99-1.htm · 6-K · 2026-11-04
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com ───────────────────────────────────────── November 4, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Ltd. (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRRE…
Read attachment ↗rdy0957_ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com ───────────────────────────────────────── October 29, 2026 National Stock Exchange of India Ltd. (Stock Code: DRREDDY) BSE Limited (Stock Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: D…
Read attachment ↗rdy0956_ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com October 28, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Ref: Disclosure u…
Read attachment ↗rdy0955_ex99-1.htm · 6-K · 2026-10-26
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com ───────────────────────────────────────── October 24, 2026 National Stock Exchange of India Ltd. (Stock Code: DRREDDY) BSE Limited (Stock Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: D…
Read attachment ↗rdy0954_ex99-1.htm · 6-K · 2026-10-26
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com ───────────────────────────────────────── October 23, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited. (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DR…
Read attachment ↗